474 related articles for article (PubMed ID: 25620635)
1. The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches.
Soltani Z; Washco V; Morse S; Reisin E
Curr Hypertens Rep; 2015 Feb; 17(2):7. PubMed ID: 25620635
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome.
Cohen JB; Cohen DL
Curr Hypertens Rep; 2015 May; 17(5):34. PubMed ID: 25833456
[TBL] [Abstract][Full Text] [Related]
3. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
Sowers JR; Whaley-Connell A; Epstein M
Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.
Cooper SA; Whaley-Connell A; Habibi J; Wei Y; Lastra G; Manrique C; Stas S; Sowers JR
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2009-23. PubMed ID: 17586614
[TBL] [Abstract][Full Text] [Related]
5. Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome.
Chen J; Townsend RR
Expert Opin Pharmacother; 2007 Sep; 8(13):2001-9. PubMed ID: 17714054
[TBL] [Abstract][Full Text] [Related]
6. [Renal markers and predictors, and renal and cardiovascular risk factors].
Fernández-Andrade C
Nefrologia; 2002; 22 Suppl 1():2-29. PubMed ID: 11987667
[TBL] [Abstract][Full Text] [Related]
7. Leptin, obesity and cardiovascular disease.
Correia ML; Haynes WG
Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):215-23. PubMed ID: 15202616
[TBL] [Abstract][Full Text] [Related]
8. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease.
Patel SB; Reams GP; Spear RM; Freeman RH; Villarreal D
Curr Hypertens Rep; 2008 Apr; 10(2):131-7. PubMed ID: 18474180
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular consequences of metabolic syndrome.
Tune JD; Goodwill AG; Sassoon DJ; Mather KJ
Transl Res; 2017 May; 183():57-70. PubMed ID: 28130064
[TBL] [Abstract][Full Text] [Related]
10. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases.
Rüster C; Wolf G
Semin Nephrol; 2013 Jan; 33(1):44-53. PubMed ID: 23374893
[TBL] [Abstract][Full Text] [Related]
11. Obesity-hypertension: emerging concepts in pathophysiology and treatment.
Mathew B; Patel SB; Reams GP; Freeman RH; Spear RM; Villarreal D
Am J Med Sci; 2007 Jul; 334(1):23-30. PubMed ID: 17630587
[TBL] [Abstract][Full Text] [Related]
12. Molecular links between obesity and cardiovascular disease.
Sorisky A
Am J Ther; 2002; 9(6):516-21. PubMed ID: 12424510
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and the sympathetic nervous system.
Egan BM
Curr Hypertens Rep; 2003 Jun; 5(3):247-54. PubMed ID: 12724058
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of hypertension in the cardiometabolic syndrome.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G
J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and the cardiometabolic syndrome.
Manrique C; Lastra G; Whaley-Connell A; Sowers JR
J Clin Hypertens (Greenwich); 2005 Aug; 7(8):471-6. PubMed ID: 16103758
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.
Sarzani R; Salvi F; Dessì-Fulgheri P; Rappelli A
J Hypertens; 2008 May; 26(5):831-43. PubMed ID: 18398321
[TBL] [Abstract][Full Text] [Related]
17. The heart in obesity-hypertension.
Morse SA; Bravo PE; Morse MC; Reisin E
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):647-58. PubMed ID: 16076275
[TBL] [Abstract][Full Text] [Related]
18. The relationship between hyperinsulinemia, hypertension and progressive renal disease.
El-Atat FA; Stas SN; McFarlane SI; Sowers JR
J Am Soc Nephrol; 2004 Nov; 15(11):2816-27. PubMed ID: 15504934
[TBL] [Abstract][Full Text] [Related]
19. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches.
Reisin E; Jack AV
Med Clin North Am; 2009 May; 93(3):733-51. PubMed ID: 19427502
[TBL] [Abstract][Full Text] [Related]
20. Resistant hypertension in the high-risk metabolic patient.
Chaudhary K; Buddineni JP; Nistala R; Whaley-Connell A
Curr Diab Rep; 2011 Feb; 11(1):41-6. PubMed ID: 20941645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
